Hearing loss and vestibular dysfunction among children with cancer after receiving aminoglycosides

Pediatric Blood and Cancer

Volumn 60, Issue 11, 2013, Pages 1772-1777

  Chen, Kenneth S ^a,b   Bach, Alicia ^b   Shoup, Angela ^a   Winick, Naomi J ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Aminoglycoside; Late effects; Ototoxicity

Indexed keywords

AMIKACIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTIBIOTIC THERAPY; ARTICLE; AUDITORY SCREENING; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; HEARING IMPAIRMENT; HEARING TEST; HODGKIN DISEASE; HUMAN; MALE; OTOTOXICITY; PERCEPTION DEAFNESS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SOLID TUMOR; T CELL LYMPHOMA; TREATMENT DURATION; VESTIBULAR DISORDER;

AMINOGLYCOSIDE; LATE EFFECTS; OTOTOXICITY;

AMIKACIN; AMINOGLYCOSIDES; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HEARING LOSS; HUMANS; MALE; NEOPLASMS; VESTIBULAR DISEASES; VESTIBULAR EVOKED MYOGENIC POTENTIALS;

EID: 84883777478     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24631     Document Type: Article

References (32)

1. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355:1572-1582.
2. Mody R, Li S, Dover D, et al. 25 year follow-up among survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor study. Blood 2008; 111:5515-5523.
3. Gurney JG, Tersak JM, Ness KK, et al. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: A report from the Children's Oncology Group. Pediatrics 2007; 120:e1229-e1236.
4. Selimoglu E, Aminoglycoside-induced ototoxicity. Curr Pharm Design 2007; 13:119-126.
5. Warchol ME. Cellular mechanisms of aminoglycoside ototoxicity. Curr Opin Otolaryngol Head Neck Surg 2010; 18:454-458.
6. Segal JA, Skolnick P. Polyamine-like actions of aminoglycosides and aminoglycoside derivatives at NMDA receptors. Eur J Pharmacol 1998; 347:311-317.
7. Tang HY, Hutcheson E, Neill S, et al. Genetic susceptibility to aminoglycoside ototoxicity: How many are at risk? Genet Med 2002; 4:336-345.
8. Gurtler N, Schmuziger N, Kim Y, et al. Audiologic testing and molecular analysis of 12S rRNA in patients receiving aminoglycosides. Laryngoscope 2005; 115:640-644.
9. Bitner-Glindzicz M, Pembrey M, Duncan A, et al. Prevalence of mitochondrial 1555A→G mutation in European children. N Engl J Med 2009; 360:640-642.
10. Vandebona H, Mitchell P, Manwaring N, et al. Prevalence of mitochondrial 1555A→G mutation in adults of European descent. N Engl J Med 2009; 360:642-644.
11. Dai P, Liu X, Han D, et al. Extremely low penetrance of deafness associated with the mitochondrial 12S rRNA mutation in 16 Chinese families: Implication for early detection and prevention of deafness. Biochem Biophys Res Commun 2006; 340:194-199.
12. Veenstra DL, Harris J, Gibson RL, et al. Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: Potential impact on clinical, patient, and economic outcomes. Genet Med 2007; 9:695-704.
13. Mulheran M, Degg C, Burr S, et al. Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy. Antimicrob Agents Chemother 2001; 45:2502-2509.
14. Charnas R, Luthi AR, Ruch W. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on antimicrobial treatment of febrile Neutropenia in children. Pediatr Infect Dis J 1997; 16:346-353.
15. El Bakri F, Pallett A, Smith AG, et al. Ototoxicity induced by once-daily gentamicin. Lancet 1998; 351:1407-1408.
16. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, et al. Extended-interval aminoglycoside administration for children: A meta-analysis. Pediatrics 2004; 114:e111-e118.
17. Kuo SW, Yang TH, Young YH. 2005; Changes in vestibular evoked myogenic potentials after Meniere attacks. Ann Otol Rhinol Laryngol 114:717-721.
18. Murofushi T, Shimizu K, Takegoshi H, et al. 2001; Diagnostic value of prolonged latencies in the vestibular evoked myogenic potential. Arch Otolaryngol 127:1069-1072.
19. Suzuki M, Yamada C, Inoue R, et al. 2008; Analysis of vestibular testing in patients with vestibular schwannoma based on the nerve of origin, the localization, and the size of the tumor. Otol Neurotol 29:1029-1033.
20. Kim HA, Hong JH, Lee H, et al. 2008; Otolith dysfunction in vestibular neuritis: Recovery pattern and a predictor of symptom recovery. Neurology 70:449-453.
21. Brantberg K, Bergenius J, Tribukait A. 1999; Vestibular-evoked myogenic potentials in patients with dehiscence of the superior semicircular canal. Acta Otolaryngol 119:633-640.
22. Patko T, Simo M, Aranyi Z. 2007; Vestibular click-evoked myogenic potentials: Sensitivity and factors determining abnormality in patients with multiple sclerosis. Mult Scler 13:193-198.
23. Chen CH, Young YH. 2003; Vestibular evoked myogenic potentials in brainstem stroke. Laryngoscope 113:990-993.
24. Akin FW, Murnane OD. 2001; Vestibular evoked myogenic potentials: Preliminary results. J Am Acad Audiol 12:445-452.
25. Akin FW, Murnane OD, Proffitt TM. 2003; The effects of click and tone-burst stimulus parameters on the vestibular evoked myogenic potential (VEMP). J Am Acad Audiol 14:500-509.
26. Campbell KC, Meech RP, Klemens JJ, et al. Prevention of noise- and drug-induced hearing loss with d-methionine. Hear Res 2007; 226:92-103. Epub 2007 Jan 16.
27. Sha SH, Qiu JH, Schacht J. Aspirin to prevent gentamicin-induced hearing loss. N Engl J Med 2006; 354:1856-1857.
28. Feldman L, Efrati S, Eviatar E, et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int 2007; 72:359-363.
29. Asplund MS, Lidian A, Linder B, et al. Protective effect of edaravone against tobramycin-induced ototoxicity. Acta Otolaryngol 2009; 129:8-13.
30. National Institute on Deafness and Other Communication Disorders (NIDCD). Outcomes research in children with hearing loss: Statistical report: Prevalence of hearing loss 2006. Available from http://www.nidcd.nih.gov/funding/programs/hb/outcomes/report.htm Accessed on Mar 23, 2009.
31. American Speech-Language-Hearing Association. 1997; Guidelines for Audiologic Screening [Guidelines]. Available from www.asha.org/policy.
32. Medeiros IR, Bittar RS, Pedalini ME, et al. Vestibular rehabilitation therapy in children. Otol Neurotol 2005; 26:699-703.